Recently, there has been an increase in interest in the genomics industry. The main reason for this has been the ARKG ETF, which Cathie Wood manages. The ARKG ETF has the following description:

“This actively managed equity strategy seeks long-term capital growth by investing in the US listed securities, including ADRs, of companies focused on the genomics revolution. Companies within this strategy aim to capture the substantial benefits of new products and services associated with technological and scientific developments in DNA sequencing, gene editing, targeted therapeutics, bioinformatics, and agricultural biology.”